Amgen, Inc. vs Dow Inc — how do they compare? Amgen, Inc. trades at $412.77 (market cap $224.14B), while Dow Inc trades at $31.24 (market cap $22.58B). The key difference: Amgen, Inc. is far larger — about 9.9× Dow Inc's market cap, and Dow Inc pays the higher dividend (4.48%). Which is the better fit depends on your goals.
| AMGN | DOW | |
|---|---|---|
Market Cap | $224.14B | $22.58B |
Sector | Health | Basic Materials |
52-Week High | $417.20 | $41.87 |
52-Week Low | $271.18 | $20.65 |
Enterprise Value | $267.45B | $38.27B |
Dividend Yield | 2.43% | 4.48% |
Trailing returns across standard periods
Latest headlines on both assets
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →Dow Inc is a diversified chemical manufacturing company. It combining science and technology to develop innovative solutions that are essential to human progress. Dow's portfolio is comprised of six global business units, organized into three operating segments: Packaging & Specialty Plastics, Industrial Intermediates & Infrastructure, and Performance Materials & Coatings.
Read more on DOW →